Advertisement
Screener

IDEAYA Biosciences, Inc. (IDYA) Graph

IDYA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $8.86M; Research and development $108.69M; Operating expenses $131.15M; Income tax (m).
  • 2026-03-31: Revenue $6.56M; Research and development $95.73M; Operating expenses $115.10M; Income tax $0.00.
  • 2025-12-31: Revenue $10.88M*; Research and development $86.60M; Operating expenses $105.45M*; Income tax $0.00*.
  • 2025-09-30: Revenue $207.83M; Research and development $82.99M; Operating expenses $99.38M; Income tax (m).

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

IDYA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$8.86MOperating expenses$131.15MOperating income-$122.29MResearch & development$108.69MNet income-$112.45M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$8.86M$108.69M$131.15M(m)-$112.45M
2026-03-31$6.56M$95.73M$115.10M$0.00-$98.54M
2025-12-31$10.88M*$86.60M$105.45M*$0.00*-$83.27M*
2025-09-30$207.83M$82.99M$99.38M(m)$119.24M
2025-06-30(m)$74.23M$88.81M$0.00-$77.49M
2025-03-31(m)$70.89M$84.39M$0.00-$72.18M
2024-09-30$0.00$57.15M$66.89M$0.00-$51.82M
2024-06-30$0.00$54.53M$64.93M$0.00-$52.77M
2024-03-31$0.00$42.80M$51.02M$0.00-$39.57M
2023-09-30$8.04M$33.70M$41.56M$0.00-$27.44M
2023-06-30$3.54M$29.18M$36.25M$0.00-$27.93M
2023-03-31$7.88M$27.86M$34.16M$0.00-$23.64M
2022-09-30$29.70M$22.37M$29.04M$0.00$1.61M
2022-06-30$5.85M$22.80M$28.35M$0.00-$22.06M
2022-03-31$11.36M$19.66M$25.58M$0.00-$14.01M
2021-09-30$8.98M$15.50M$20.69M$0.00-$11.58M
2021-06-30$8.76M$14.98M$19.81M$0.00-$10.95M
2021-03-31$7.25M$11.57M$16.38M$0.00-$9.02M
2020-09-30$8.97M$10.03M$13.96M$0.00-$4.93M
2020-06-30(m)$8.60M$12.59M$0.00-$12.39M
2020-03-31(m)$9.03M$12.48M$0.00-$12.04M
2019-12-31(m)(m)$11.32M(m)-$10.78M
2019-09-30(m)$8.92M$11.62M$0.00-$10.97M
2019-06-30(m)$8.86M$11.23M$0.00-$10.66M
2019-03-31(m)$8.00M$10.09M$0.00-$9.57M
2018-12-31(m)(m)$9.13M(m)-$8.56M
2018-09-30(m)$12.54M$13.63M$0.00-$13.05M
2018-06-30(m)$6.43M$7.57M$0.00-$7.00M
2018-03-31(m)(m)$6.09M(m)-$5.74M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$15.42M$204.41M$246.25M$0.00-$210.99M
2025-06-30(m)$145.11M$173.19M$0.00-$149.67M
2024-06-30$0.00$97.34M$115.94M$0.00-$92.34M
2023-06-30$11.42M$57.04M$70.41M$0.00-$51.57M
2022-06-30$17.21M$42.45M$53.93M$0.00-$36.07M
2021-06-30$16.00M$26.55M$36.19M$0.00-$19.97M
2020-06-30(m)$17.62M$25.07M$0.00-$24.43M
2019-06-30(m)$16.86M$21.33M$0.00-$20.23M
2018-06-30(m)$11.63M$13.66M$0.00-$12.73M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$207.83M$228.10M$272.58M$0.00-$30.43M
2024-09-30$0.00$154.49M$182.84M$0.00-$144.16M
2023-09-30$19.46M$90.74M$111.97M$0.00-$79.01M
2022-09-30$46.91M$64.82M$82.97M$0.00-$34.45M
2021-09-30$24.98M$42.05M$56.88M$0.00-$31.55M
2020-09-30$8.97M$27.65M$39.03M$0.00-$29.36M
2019-09-30(m)$25.78M$32.95M$0.00-$31.19M
2018-09-30(m)$24.17M$27.28M$0.00-$25.78M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$218.71M$314.70M$378.02M$0.00-$113.70M
2024-12-31$7.00M$294.67M$333.98M$0.00-$274.48M
2023-12-31$23.39M$129.51M$157.81M$0.00-$112.96M
2022-12-31$50.93M$89.54M$113.43M$0.00-$58.66M
2021-12-31$27.94M$58.16M$78.21M$0.00-$49.76M
2020-12-31$19.54M$39.70M$54.88M$0.00-$34.49M
2019-12-31$0.00$34.32M$44.27M$0.00-$41.98M
2018-12-31(m)$31.75M$36.42M$0.00-$34.35M
2017-12-31(m)$12.38M$14.44M(m)-$11.86M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Organon & Co. (OGN)United States$3.603B17.03
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53